{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:06:52Z","timestamp":1777774012694,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40121-026-01319-2","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:34:27Z","timestamp":1772012067000},"page":"1263-1279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preparing for Tuberculosis Vaccine M72\/AS01E Implementation: A Global Demand Forecast and Key Influential Factors"],"prefix":"10.1007","volume":"15","author":[{"given":"Judith","family":"Kallenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Milea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2532-0505","authenticated-orcid":false,"given":"Thomas","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6938-2665","authenticated-orcid":false,"given":"Agathe","family":"Philippot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"1319_CR1","unstructured":"World Health Organization (WHO). Global tuberculosis report 2024. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024. Accessed May 27 2025."},{"key":"1319_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107876","volume":"155","author":"B Sossen","year":"2025","unstructured":"Sossen B, Kubjane M, Meintjes G. Tuberculosis and HIV coinfection: progress and challenges towards reducing incidence and mortality. Int J Infect Dis. 2025;155:107876. https:\/\/doi.org\/10.1016\/j.ijid.2025.107876.","journal-title":"Int J Infect Dis"},{"issue":"8","key":"1319_CR3","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1021\/acsinfecdis.4c00466","volume":"10","author":"TKA Teibo","year":"2024","unstructured":"Teibo TKA, Andrade RLP, Rosa RJ, et al. Barriers that interfere with access to tuberculosis diagnosis and treatment across countries globally: a systematic review. ACS Infect Dis. 2024;10(8):2600\u201314. https:\/\/doi.org\/10.1021\/acsinfecdis.4c00466.","journal-title":"ACS Infect Dis"},{"key":"1319_CR4","unstructured":"European Lung Foundation (ELF). Multidrug-resistant tuberculosis (MDR-TB). https:\/\/europeanlung.org\/en\/information-hub\/lung-conditions\/multidrug-resistant-tuberculosis-mdr-tb\/ Accessed May 27 2025."},{"key":"1319_CR5","unstructured":"World Health Organization (WHO). Antimicrobial resistance 2024. https:\/\/www.who.int\/europe\/news-room\/fact-sheets\/item\/antimicrobial-resistance. Accessed 08 July 2025."},{"issue":"3","key":"1319_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119332","volume":"10","author":"K Chung-Delgado","year":"2015","unstructured":"Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A. Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS ONE. 2015;10(3):e0119332. https:\/\/doi.org\/10.1371\/journal.pone.0119332.","journal-title":"PLoS ONE"},{"key":"1319_CR7","unstructured":"World Health Organization (WHO). Global programme on tuberculosis & lung health - New TB vaccine research. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/research-innovation\/vaccines. Accessed May 27 2025."},{"key":"1319_CR8","unstructured":"World Health Organization (WHO). Global tuberculosis report 2022. https:\/\/www.iom.int\/sites\/g\/files\/tmzbdl486\/files\/documents\/2023-03\/Global-TB-Report-2022.pdf. Accessed 19 Aug 2025."},{"key":"1319_CR9","unstructured":"United Nations. Political declaration of the high-level meeting on the fight against tuberculosis 2023. Available from: https:\/\/docs.un.org\/en\/A\/RES\/78\/5. Accessed 09 Sep 2025."},{"key":"1319_CR10","unstructured":"Gavi.org. Gavi Vaccine Investment Strategy (VIS) 2024 decisions 2025. https:\/\/www.gavi.org\/our-alliance\/strategy\/vaccine-investment-strategy-2024#decisions. Accessed May 27 2025."},{"key":"1319_CR11","unstructured":"World Health Organization (WHO). Tuberculosis Vaccine Accelerator Council 2023. https:\/\/www.who.int\/initiatives\/tuberculosis-vaccine-accelerator-council. Accessed 27 May 2025."},{"key":"1319_CR12","unstructured":"World Health Organization (WHO). WHO preferred product characteristics for new tuberculosis vaccines 2018. https:\/\/iris.who.int\/bitstream\/handle\/10665\/273089\/WHO-IVB-18.06-eng.pdf?ua=1. Accessed 10 June 2025."},{"issue":"25","key":"1319_CR13","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1909953.","journal-title":"N Engl J Med"},{"key":"1319_CR14","unstructured":"Han L. Safety and immunogenicity of the investigational tuberculosis vaccine M72\/AS01E-4 in people living with HIV 2023. https:\/\/www.gatesmri.org\/wp-content\/uploads\/2024\/02\/102023-mesa-trial-tb-union-oct28.pdf. Accessed 27 May 2025."},{"key":"1319_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(25)00124-9","author":"AF Dagnew","year":"2025","unstructured":"Dagnew AF, Han LL, Naidoo K, et al. Safety and immunogenicity of investigational tuberculosis vaccine M72\/AS01E\u20134 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. Lancet HIV. 2025. https:\/\/doi.org\/10.1016\/s2352-3018(25)00124-9.","journal-title":"Lancet HIV"},{"key":"1319_CR16","unstructured":"Clinicaltrials.gov. Study to assess efficacy and safety of M72\/\u200bAS01E-4 Mycobacterium tuberculosis (M. tb) vaccine in adolescents and adults 2025. https:\/\/clinicaltrials.gov\/study\/NCT06062238 Accessed 09 June 2025."},{"key":"1319_CR17","unstructured":"Wellcome Open Research. Conducting market analyses for new tuberculosis vaccines for adolescents and adults: a summary of one approach applied to M72\/AS01E 2024. https:\/\/wellcomeopenresearch.org\/documents\/9-372. Accessed 28 May 2025."},{"key":"1319_CR18","unstructured":"Gavi.org. Vaccine Investment Strategy 2024 - Appendix 4: Tuberculosis investment case 2024. https:\/\/www.gavi.org\/sites\/default\/files\/committees\/ppc\/minutes\/2024\/Appendix-4-Tuberculosis_investment-case.pdf. Accessed 2 June 2025."},{"key":"1319_CR19","unstructured":"Gavi.org. Forecasting global demand for novel TB vaccines: scenarios for early planning and needs assessment 2025. https:\/\/www.gavi.org\/sites\/default\/files\/about\/market-shaping\/Forecasting-global-demand-for-novel-TB-vaccines_ENG.pdf Accessed 9 Oct 2025."},{"key":"1319_CR20","unstructured":"World Health Organization (WHO). Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage 2024. https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/diphtheria-tetanus-toxoid-and-pertussis-(dtp)-vaccination-coverage?GROUP=Countries&ANTIGEN=DTPCV3&YEAR=&CODE. Accessed 27 Oct 2025."},{"key":"1319_CR21","unstructured":"World Bank Group. Population estimates and projections 2025. https:\/\/databank.worldbank.org\/source\/population-estimates-and-projections Accessed 12 Aug 2025."},{"key":"1319_CR22","unstructured":"World Health Organization (WHO). Tuberculosis data 2025. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data#csv_files. Accessed 12 Aug 2025."},{"key":"1319_CR23","unstructured":"World Health Organization (WHO). HIV\u2014number of people living with HIV 2025. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/estimated-number-of-people--living-with-hiv. Accessed 12 Aug 2025."},{"key":"1319_CR24","unstructured":"World Health Organization (WHO). Immunization data 2024. https:\/\/immunizationdata.who.int\/global?topic=&location Accessed 27 Oct 2025."},{"key":"1319_CR25","unstructured":"World Bank Group. Antiretroviral therapy coverage (% of adults living with HIV) 2025. https:\/\/genderdata.worldbank.org\/en\/indicator\/sh-hiv-artc-zs. Accessed 12 Aug 2025."},{"key":"1319_CR26","unstructured":"UNAIDS. Country files 2025. https:\/\/www.unaids.org\/en\/regionscountries\/countries. Accessed 12 Aug 2025."},{"issue":"6","key":"1319_CR27","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1016\/s2214-109x(25)00062-2","volume":"13","author":"W Mao","year":"2025","unstructured":"Mao W, Hodges EU, Zimmerman A, et al. Development, launch, and scale-up of health products in low-income and middle-income countries: a retrospective analysis on 59 health products. Lancet Glob Health. 2025;13(6):e1132\u20139. https:\/\/doi.org\/10.1016\/s2214-109x(25)00062-2.","journal-title":"Lancet Glob Health"},{"key":"1319_CR28","unstructured":"Strategic Advisory Group of Experts (SAGE) on Immunization. Working Group on potential contribution of HPV vaccines and immunization towards cervical cancer elimination 2022. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/position_paper_documents\/human-papillomavirus-(hpv)\/hpv-background-document--report-march-2022.pdf. Accessed 08 July 2025."},{"issue":"10","key":"1319_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182663","volume":"12","author":"S Botwright","year":"2017","unstructured":"Botwright S, Holroyd T, Nanda S, et al. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects. PLoS ONE. 2017;12(10):e0182663. https:\/\/doi.org\/10.1371\/journal.pone.0182663.","journal-title":"PLoS ONE"},{"key":"1319_CR30","unstructured":"World Health Organization (WHO). Revising global indicative wastage rates: a WHO initiative for better planning and forecasting of vaccine supply needs 2019. https:\/\/www.who.int\/docs\/default-source\/immunization\/tools\/revising-wastage-concept-note.pdf. Accessed 08 July 2025."},{"key":"1319_CR31","unstructured":"World Health Organization (WHO). Full evidence report on the RTS,S\/AS01 malaria vaccine 2021. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/mvip\/full-evidence-report-on-the-rtss-as01-malaria-vaccine-for-sage-mpag-(sept2021).pdf. Accessed 10 July 2025."},{"key":"1319_CR32","unstructured":"European Medicines Agency (EMA). First malaria vaccine receives positive scientific opinion from EMA 2015. https:\/\/www.ema.europa.eu\/en\/news\/first-malaria-vaccine-receives-positive-scientific-opinion-ema. Accessed 13 Aug 2025."},{"key":"1319_CR33","unstructured":"World Health Organization (WHO). Malaria vaccines: WHO Position Paper\u2014January 2016. Wkly Epidemiol Rec. 2016;4(91):33\u201351."},{"key":"1319_CR34","unstructured":"World Health Organization (WHO). Malaria vaccine: WHO position paper\u2014March 2022. Wkly Epidemiol Rec 2021;9(97):61\u201380."},{"issue":"10031","key":"1319_CR35","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/S0140-6736(16)30394-4","volume":"387","author":"KL O'Brien","year":"2016","unstructured":"O\u2019Brien KL, Binka F, Marsh K, Abramson JS. Mind the gap: jumping from vaccine licensure to routine use. Lancet. 2016;387(10031):1887\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(16)30394-4.","journal-title":"Lancet"},{"key":"1319_CR36","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1016\/S1473-3099(25)00245-2","volume":"25","author":"T Burki","year":"2025","unstructured":"Burki T. Gavi under threat from US funding cuts. Lancet Infect Dis. 2025;25:e266\u20137. https:\/\/doi.org\/10.1016\/S1473-3099(25)00245-2.","journal-title":"Lancet Infect Dis"},{"key":"1319_CR37","unstructured":"World Health Organization (WHO). Leave no one behind: guidance for planning and implementing catch-up vaccination 2021. https:\/\/iris.who.int\/bitstream\/handle\/10665\/340749\/9789240016514-eng.pdf. Accessed 11 June 2025."},{"key":"1319_CR38","unstructured":"JSI.org. Development of catch-up vaccination guidelines in Ethiopia: Process documentation and lessons learned 2021. https:\/\/publications.jsi.com\/JSIInternet\/Inc\/Common\/_download_pub.cfm?id=25839&lid=3. Accessed 10 June 2025."}],"updated-by":[{"DOI":"10.1007\/s40121-026-01338-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01319-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:34:29Z","timestamp":1777484069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01319-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01319-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The copyright holder for this article was incorrectly given as \u2018The Author(s)\u2019 but should have been \u2018GSK Plc.\u2019.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-026-01338-z","URL":"https:\/\/doi.org\/10.1007\/s40121-026-01338-z","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Judith Kallenberg, Dominique Milea, Thomas Breuer, and Agathe Philippot are GSK employees and hold financial equities in GSK. Judith Kallenberg, Dominique Milea, Thomas Breuer, and Agathe Philippot declare no other financial and non-financial relationships and activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and published data, and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"AS01 is a trademark owned by or licensed to the GSK group of companies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademark"}}]}}